United Capital Financial Advisors LLC Buys Shares of 1,366 Medpace Holdings, Inc. $MEDP

United Capital Financial Advisors LLC acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,366 shares of the company’s stock, valued at approximately $723,000.

Several other hedge funds have also modified their holdings of the business. Johnson Financial Group Inc. acquired a new position in shares of Medpace during the 2nd quarter worth $27,000. Geneos Wealth Management Inc. raised its holdings in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Elyxium Wealth LLC purchased a new stake in Medpace during the fourth quarter worth $30,000. Jones Financial Companies Lllp purchased a new stake in Medpace during the second quarter worth $30,000. Finally, Allied Private Wealth LLC acquired a new stake in Medpace in the second quarter valued at $31,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Price Performance

NASDAQ MEDP opened at $600.65 on Monday. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The business has a fifty day moving average of $565.33 and a 200-day moving average of $494.30. The stock has a market cap of $16.76 billion, a price-to-earnings ratio of 35.21, a price-to-earnings-growth ratio of 2.68 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter last year, the company earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Analyst Upgrades and Downgrades

MEDP has been the subject of several research reports. Royal Bank Of Canada lifted their price target on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Truist Financial increased their price objective on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. BMO Capital Markets upped their price target on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a report on Friday, July 24th. Finally, Barclays set a $600.00 price target on shares of Medpace in a report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $584.18.

Insider Activity

In other Medpace news, VP Susan E. Burwig sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the sale, the vice president directly owned 62,984 shares of the company’s stock, valued at $37,790,400. This trade represents a 10.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Brian T. Carley sold 5,000 shares of Medpace stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the sale, the director owned 27,825 shares of the company’s stock, valued at approximately $16,935,129.75. This trade represents a 15.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 133,821 shares of company stock valued at $81,748,135 in the last 90 days. Company insiders own 20.50% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.